VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011 Mar 01; 29(7):789-96.
View in:
PubMed
subject areas
Adult
Aged
Aged, 80 and over
Cytokines
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug-Related Side Effects and Adverse Reactions
Female
Follow-Up Studies
Humans
Janus Kinase 2
Male
Maximum Tolerated Dose
Middle Aged
Polycythemia Vera
Primary Myelofibrosis
Pyrrolidines
Risk Assessment
Severity of Illness Index
Sulfonamides
Thrombocythemia, Essential
Time Factors
Treatment Outcome
authors with profiles
JORGE E CORTES